Table 3.

Creatinine clearance and dietary sodium, potassium, and protein intake^a

Variable	Treatment	Week			P valueb
		0	24	48
Sample sizec
	Placebo	27	22	21
	Losartan	26	23	21
	Spironolactone	27	20	17
Creatinine clearance, ml/min					0.80
	Placebo	73.0 [59.6–89.4]	67.5 [54.4–83.8]	64.3 [49.6–83.4]
	Losartan	64.8 [53–79.2]	60.5 [49.6–73.7]	54.1 [40.5–72.2]
	Spironolactone	51.4 [40.1–65.8]	48.1 [36.2–64.0]	51.6 [39.6–67.4]
24-h urinary sodium, mEq/d					0.28
	Placebo	193 [161–225]	223 [169–278]	196 [147–245]
	Losartan	220 [189–251]	206 [169–243]	213 [164–262]
	Spironolactone	219 [169–270]	220 [171–268]	221 [165–277]
24-h urinary potassium, mEq/d					0.11
	Placebo	56.8 [49.5–64]	59 [48.5–69.4]	53.4 [43.3–63.5]
	Losartan	62.7 [56.6–68.9]	58.3 [51.4–65.1]	51.8 [44.5–59.1]
	Spironolactone	57.6 [50.2–65]	53.8 [45.3–62.4]	54.5 [42.6–66.5]
Normalized protein catabolic rate, g/kg/d					0.18
	Placebo	0.97 [0.89–1.06]	1.03 [0.9–1.15]	0.98 [0.88–1.09]
	Losartan	1.07 [0.96–1.18]	1.02 [0.86–1.19]	1.02 [0.83–1.21]
	Spironolactone	0.91 [0.83–1]	0.93 [0.83–1.03]	0.98 [0.87–1.09]

^aData are presented as mean [95% CI]. Geometric means are reported for creatinine clearance.

^bP value represents the between-group treatment effect from a mixed-model repeated-measures analysis of weeks 0 to 48.

^cSample size indicates the number of subjects remaining at each evaluation.